FR901228A
(fr)
|
1943-01-16 |
1945-07-20 |
Deutsche Edelstahlwerke Ag |
Système d'aimant à entrefer annulaire
|
US2779780A
(en)
|
1955-03-01 |
1957-01-29 |
Du Pont |
1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation
|
US4261989A
(en)
|
1979-02-19 |
1981-04-14 |
Kaken Chemical Co. Ltd. |
Geldanamycin derivatives and antitumor drug
|
US4433059A
(en)
|
1981-09-08 |
1984-02-21 |
Ortho Diagnostic Systems Inc. |
Double antibody conjugate
|
US4444878A
(en)
|
1981-12-21 |
1984-04-24 |
Boston Biomedical Research Institute, Inc. |
Bispecific antibody determinants
|
US4851332A
(en)
|
1985-04-01 |
1989-07-25 |
Sloan-Kettering Institute For Cancer Research |
Choriocarcinoma monoclonal antibodies and antibody panels
|
US5869620A
(en)
|
1986-09-02 |
1999-02-09 |
Enzon, Inc. |
Multivalent antigen-binding proteins
|
US5114946A
(en)
|
1987-06-12 |
1992-05-19 |
American Cyanamid Company |
Transdermal delivery of pharmaceuticals
|
US4818541A
(en)
|
1987-08-19 |
1989-04-04 |
Schering Corporation |
Transdermal delivery of enantiomers of phenylpropanolamine
|
JPH021556A
(ja)
|
1988-06-09 |
1990-01-05 |
Snow Brand Milk Prod Co Ltd |
ハイブリッド抗体及びその作製方法
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
WO1991003493A1
(en)
|
1989-08-29 |
1991-03-21 |
The University Of Southampton |
Bi-or trispecific (fab)3 or (fab)4 conjugates
|
US5273743A
(en)
|
1990-03-09 |
1993-12-28 |
Hybritech Incorporated |
Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
|
GB9012995D0
(en)
|
1990-06-11 |
1990-08-01 |
Celltech Ltd |
Multivalent antigen-binding proteins
|
US5582996A
(en)
|
1990-12-04 |
1996-12-10 |
The Wistar Institute Of Anatomy & Biology |
Bifunctional antibodies and method of preparing same
|
DE4118120A1
(de)
|
1991-06-03 |
1992-12-10 |
Behringwerke Ag |
Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
|
US6511663B1
(en)
|
1991-06-11 |
2003-01-28 |
Celltech R&D Limited |
Tri- and tetra-valent monospecific antigen-binding proteins
|
US5637481A
(en)
|
1993-02-01 |
1997-06-10 |
Bristol-Myers Squibb Company |
Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
|
AU669124B2
(en)
|
1991-09-18 |
1996-05-30 |
Kyowa Hakko Kirin Co., Ltd. |
Process for producing humanized chimera antibody
|
US5932448A
(en)
|
1991-11-29 |
1999-08-03 |
Protein Design Labs., Inc. |
Bispecific antibody heterodimers
|
AU676150B2
(en)
|
1992-01-23 |
1997-03-06 |
Merck Patent Gmbh |
Monomeric and dimeric antibody-fragment fusion proteins
|
ATE295420T1
(de)
|
1992-02-06 |
2005-05-15 |
Chiron Corp |
Marker für krebs und biosynthetisches bindeprotein dafür
|
US5646253A
(en)
|
1994-03-08 |
1997-07-08 |
Memorial Sloan-Kettering Cancer Center |
Recombinant human anti-LK26 antibodies
|
ATE165113T1
(de)
|
1992-05-08 |
1998-05-15 |
Creative Biomolecules Inc |
Mehrwertige chimäre proteine anologe und verfahren zu deren anwendungen
|
US6005079A
(en)
|
1992-08-21 |
1999-12-21 |
Vrije Universiteit Brussels |
Immunoglobulins devoid of light chains
|
US7196170B2
(en)
|
1992-09-14 |
2007-03-27 |
The General Hospital Corporation |
Aiolos, Helios, Daedalos and Ikaros: genes, polypeptides, regulatory elements and uses thereof
|
EP1550729B1
(en)
|
1992-09-25 |
2009-05-27 |
Avipep Pty Limited |
Target binding polypeptide comprising an IG-like VL domain linked to an IG-like VH domain
|
GB9221657D0
(en)
|
1992-10-15 |
1992-11-25 |
Scotgen Ltd |
Recombinant bispecific antibodies
|
US5262564A
(en)
|
1992-10-30 |
1993-11-16 |
Octamer, Inc. |
Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
|
EP0627932B1
(en)
|
1992-11-04 |
2002-05-08 |
City Of Hope |
Antibody construct
|
GB9323648D0
(en)
|
1992-11-23 |
1994-01-05 |
Zeneca Ltd |
Proteins
|
EP0672142B1
(en)
|
1992-12-04 |
2001-02-28 |
Medical Research Council |
Multivalent and multispecific binding proteins, their manufacture and use
|
US6476198B1
(en)
|
1993-07-13 |
2002-11-05 |
The Scripps Research Institute |
Multispecific and multivalent antigen-binding polypeptide molecules
|
US5635602A
(en)
|
1993-08-13 |
1997-06-03 |
The Regents Of The University Of California |
Design and synthesis of bispecific DNA-antibody conjugates
|
WO1995009917A1
(en)
|
1993-10-07 |
1995-04-13 |
The Regents Of The University Of California |
Genetically engineered bispecific tetravalent antibodies
|
AU7863794A
(en)
|
1993-11-16 |
1995-06-06 |
Pola Chemical Industries Inc. |
Antihuman tyrosinase monoclonal antibody
|
US5635388A
(en)
|
1994-04-04 |
1997-06-03 |
Genentech, Inc. |
Agonist antibodies against the flk2/flt3 receptor and uses thereof
|
CA2188432C
(en)
|
1994-04-22 |
2011-02-01 |
Yutaka Kawakami |
Melanoma antigens
|
US5786464C1
(en)
|
1994-09-19 |
2012-04-24 |
Gen Hospital Corp |
Overexpression of mammalian and viral proteins
|
WO1996013583A2
(en)
|
1994-10-20 |
1996-05-09 |
Morphosys Gesellschaft Für Proteinoptimierung Mbh |
Targeted hetero-association of recombinant proteins to multi-functional complexes
|
ES2141467T5
(es)
|
1995-01-18 |
2006-07-16 |
Roche Diagnostics Gmbh |
Anticuerpos anti-cd30 que evitan la escision proteolitica y liberacion del antigeno cd30 fijado a la membrana.
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
JPH11508126A
(ja)
|
1995-05-23 |
1999-07-21 |
モルフォシス ゲゼルシャフト ファー プロテインオプティマイルング エムベーハー |
多量体タンパク質
|
AU6873396A
(en)
|
1995-10-16 |
1997-05-07 |
Unilever N.V. |
A bifunctional or bivalent antibody fragment analogue
|
ATE254931T1
(de)
|
1996-01-05 |
2003-12-15 |
Us Gov Health & Human Serv |
Mesothelinantigen, verfahren und testsatz zur targetierung
|
DE19608769C1
(de)
|
1996-03-07 |
1997-04-10 |
Univ Eberhard Karls |
Antikörper BV10A4H2
|
DK0894135T3
(da)
|
1996-04-04 |
2004-12-06 |
Unilever Nv |
Multivalent og multispecifikt antigenbindingsprotein
|
US6114148C1
(en)
|
1996-09-20 |
2012-05-01 |
Gen Hospital Corp |
High level expression of proteins
|
WO1998017796A2
(en)
|
1996-10-25 |
1998-04-30 |
The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Methods and compositions for inhibiting inflammation and angiogenesis comprising a mammalian cd97 alpha subunit
|
WO1998049198A1
(en)
|
1997-04-30 |
1998-11-05 |
Enzon, Inc. |
Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
|
US20020062010A1
(en)
|
1997-05-02 |
2002-05-23 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
US20030207346A1
(en)
|
1997-05-02 |
2003-11-06 |
William R. Arathoon |
Method for making multispecific antibodies having heteromultimeric and common components
|
PT1012280E
(pt)
|
1997-06-11 |
2005-02-28 |
Borean Pharma As |
Modulo de trimerizacao
|
ATE461282T1
(de)
|
1997-10-27 |
2010-04-15 |
Bac Ip Bv |
Multivalente antigenbindende proteine
|
IL135775A0
(en)
|
1997-12-01 |
2001-05-20 |
Us Gov Health & Human Serv |
Antibodies and immunoconjugates having high binding affinity for mesothelin
|
DK1049787T3
(da)
|
1998-01-23 |
2005-04-04 |
Vlaams Interuniv Inst Biotech |
Antistofderivater med flere anvendelsesmuligheder
|
HUP9900956A2
(hu)
|
1998-04-09 |
2002-04-29 |
Aventis Pharma Deutschland Gmbh. |
Egyláncú, több antigéntkötőhely kialakítására képes molekulák, előállításuk és alkalmazásuk
|
DE19819846B4
(de)
|
1998-05-05 |
2016-11-24 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Multivalente Antikörper-Konstrukte
|
GB9812545D0
(en)
|
1998-06-10 |
1998-08-05 |
Celltech Therapeutics Ltd |
Biological products
|
US6803448B1
(en)
|
1998-07-22 |
2004-10-12 |
Vanderbilt University |
GBS toxin receptor
|
JP2002521053A
(ja)
|
1998-07-28 |
2002-07-16 |
マイクロメット アーゲー |
ヘテロミニ体
|
US6333396B1
(en)
|
1998-10-20 |
2001-12-25 |
Enzon, Inc. |
Method for targeted delivery of nucleic acids
|
CA2346448A1
(en)
|
1998-12-16 |
2000-06-22 |
Warner-Lambert Company |
Treatment of arthritis with mek inhibitors
|
US6528481B1
(en)
|
1999-02-16 |
2003-03-04 |
The Burnam Institute |
NG2/HM proteoglycan-binding peptides that home to angiogenic vasculature and related methods
|
US7534866B2
(en)
|
2005-10-19 |
2009-05-19 |
Ibc Pharmaceuticals, Inc. |
Methods and compositions for generating bioactive assemblies of increased complexity and uses
|
US7527787B2
(en)
|
2005-10-19 |
2009-05-05 |
Ibc Pharmaceuticals, Inc. |
Multivalent immunoglobulin-based bioactive assemblies
|
RS51157B
(sr)
|
1999-08-17 |
2010-10-31 |
Biogen Idec Ma Inc. |
Baff receptor (bcma), imunoregulatorni agens
|
EP1238985B1
(en)
|
1999-09-30 |
2008-03-05 |
Kyowa Hakko Kogyo Co., Ltd. |
Human type complementarity determining region transplantation antibody against ganglioside gd3 and derivatives of antibody against ganglioside gd3
|
ES2568625T3
(es)
|
1999-11-29 |
2016-05-03 |
The Trustees Of Columbia University In The City Of New York |
Aislamiento de cinco genes novedosos que codifican nuevos melanomas de tipo receptor de Fc implicados en la patogénesis del linfoma/melanoma
|
ES2629683T3
(es)
|
1999-11-30 |
2017-08-14 |
Mayo Foundation For Medical Education And Research |
B7-H1, una nueva molécula inmunorreguladora
|
GB0000313D0
(en)
|
2000-01-10 |
2000-03-01 |
Astrazeneca Uk Ltd |
Formulation
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
CA3036031C
(en)
|
2000-03-06 |
2021-04-13 |
Craig T. Jordan |
A compound that selectively binds to cd123 and use thereof to kill hematologic cancer progenitor cells
|
ES2637801T3
(es)
|
2000-04-11 |
2017-10-17 |
Genentech, Inc. |
Anticuerpos multivalentes y usos de los mismos
|
WO2001090192A2
(en)
|
2000-05-24 |
2001-11-29 |
Imclone Systems Incorporated |
Bispecific immunoglobulin-like antigen binding proteins and method of production
|
CA2410551A1
(en)
|
2000-06-30 |
2002-01-10 |
Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) |
Heterodimeric fusion proteins
|
DZ3401A1
(fr)
|
2000-07-19 |
2002-01-24 |
Warner Lambert Co |
Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques
|
CA2417185A1
(en)
|
2000-07-25 |
2002-01-31 |
Shui-On Leung |
Multivalent target binding protein
|
GB0020685D0
(en)
|
2000-08-22 |
2000-10-11 |
Novartis Ag |
Organic compounds
|
JP4261907B2
(ja)
|
2000-10-20 |
2009-05-13 |
中外製薬株式会社 |
低分子化アゴニスト抗体
|
US7090843B1
(en)
|
2000-11-28 |
2006-08-15 |
Seattle Genetics, Inc. |
Recombinant anti-CD30 antibodies and uses thereof
|
WO2002044372A2
(en)
|
2000-12-01 |
2002-06-06 |
Parker Hughes Institute |
Nucleotide and protein sequence of helios 3 and methods of use
|
US6995162B2
(en)
|
2001-01-12 |
2006-02-07 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
US7829084B2
(en)
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
WO2002072635A2
(en)
|
2001-03-13 |
2002-09-19 |
University College London |
Specific binding members
|
CN1294148C
(zh)
|
2001-04-11 |
2007-01-10 |
中国科学院遗传与发育生物学研究所 |
环状单链三特异抗体
|
US6770622B2
(en)
|
2001-06-08 |
2004-08-03 |
Gary A. Jarvis |
N-terminally truncated galectin-3 for use in treating cancer
|
AU2002319402B2
(en)
|
2001-06-28 |
2008-09-11 |
Domantis Limited |
Dual-specific ligand and its use
|
US6833441B2
(en)
|
2001-08-01 |
2004-12-21 |
Abmaxis, Inc. |
Compositions and methods for generating chimeric heteromultimers
|
DE60231989D1
(de)
|
2001-08-06 |
2009-05-28 |
Childrens Medical Center |
Antiangiogenese wirkung von stickstoffsubstituierten thalidomid-analoga
|
JP2005509412A
(ja)
|
2001-08-23 |
2005-04-14 |
アールエスアール リミテッド |
チロトロフィン(tsh)受容体の抗原決定領域、その使用およびその抗体
|
ES2276735T3
(es)
|
2001-09-14 |
2007-07-01 |
Affimed Therapeutics Ag |
Anticuerpos fv multimericos de cadena sencilla en tandem.
|
JP4716350B2
(ja)
|
2001-12-04 |
2011-07-06 |
ダナ−ファーバー キャンサー インスティテュート インク. |
潜伏期膜タンパク質に対する抗体およびそれらの使用
|
WO2003049684A2
(en)
|
2001-12-07 |
2003-06-19 |
Centocor, Inc. |
Pseudo-antibody constructs
|
IL162734A0
(en)
|
2002-02-01 |
2005-11-20 |
Ariad Gene Therapeutics Inc |
Phosphorus-containing compounds & uses thereof
|
EP1487879B1
(en)
|
2002-03-01 |
2012-12-26 |
Immunomedics, Inc. |
Bispecific antibody point mutations for enhancing rate of clearance
|
JP4575667B2
(ja)
|
2002-03-08 |
2010-11-04 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
医薬として有用な大環状化合物
|
SI1482932T1
(sl)
|
2002-03-13 |
2010-02-26 |
Array Biopharma Inc |
N3-alkilirani derivati benzimidazola kot inhibitorji mek
|
WO2003087163A1
(fr)
|
2002-04-15 |
2003-10-23 |
Chugai Seiyaku Kabushiki Kaisha |
Procede d'elaboration d'une banque scdb
|
TWI275390B
(en)
|
2002-04-30 |
2007-03-11 |
Wyeth Corp |
Process for the preparation of 7-substituted-3- quinolinecarbonitriles
|
US7446190B2
(en)
|
2002-05-28 |
2008-11-04 |
Sloan-Kettering Institute For Cancer Research |
Nucleic acids encoding chimeric T cell receptors
|
DE10161767T1
(de)
|
2002-07-03 |
2018-06-07 |
Honjo Tasuku |
Immunopotenzierende Zusammensetzungen, die einen Anti-PD-L1 Antikörper enthalten
|
GB0215823D0
(en)
|
2002-07-09 |
2002-08-14 |
Astrazeneca Ab |
Quinazoline derivatives
|
ATE415413T1
(de)
|
2002-07-15 |
2008-12-15 |
Univ Princeton |
Iap-bindende verbindungen
|
US20050203142A1
(en)
|
2002-10-24 |
2005-09-15 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
|
US20040087558A1
(en)
|
2002-10-24 |
2004-05-06 |
Zeldis Jerome B. |
Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
|
ES2345885T3
(es)
|
2002-11-15 |
2010-10-05 |
Novartis Vaccines And Diagnostics, Inc. |
Metodos para prevenir y tratar metastasis de cancer y perdida de hueso asociada con la metastasis de cancer.
|
EP1565492B1
(de)
|
2002-11-26 |
2006-12-20 |
B.R.A.H.M.S Aktiengesellschaft |
Nachweis von tsh-rezeptor-autoantikörpern mit affinitätsgereinigten antikörpern
|
US7521051B2
(en)
|
2002-12-23 |
2009-04-21 |
Medimmune Limited |
Methods of upmodulating adaptive immune response using anti-PD-1 antibodies
|
CA2512000C
(en)
|
2002-12-26 |
2011-08-09 |
Eisai Co., Ltd. |
Selective estrogen receptor modulator
|
GB0230203D0
(en)
|
2002-12-27 |
2003-02-05 |
Domantis Ltd |
Fc fusion
|
GB0305702D0
(en)
|
2003-03-12 |
2003-04-16 |
Univ Birmingham |
Bispecific antibodies
|
WO2004087758A2
(en)
|
2003-03-26 |
2004-10-14 |
Neopharm, Inc. |
Il 13 receptor alpha 2 antibody and methods of use
|
AU2004232928A1
(en)
|
2003-04-22 |
2004-11-04 |
Ibc Pharmaceuticals |
Polyvalent protein complex
|
US7479546B2
(en)
|
2003-06-27 |
2009-01-20 |
Diadexus, Inc. |
Pro104 antibody compositions and methods of use
|
CA2529945A1
(en)
|
2003-06-27 |
2005-01-06 |
Biogen Idec Ma Inc. |
Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
|
US20050100543A1
(en)
|
2003-07-01 |
2005-05-12 |
Immunomedics, Inc. |
Multivalent carriers of bi-specific antibodies
|
US7696322B2
(en)
|
2003-07-28 |
2010-04-13 |
Catalent Pharma Solutions, Inc. |
Fusion antibodies
|
JP2007525971A
(ja)
|
2003-08-05 |
2007-09-13 |
モルフォテック、インク. |
癌に関連する変異体細胞表面分子
|
US7399865B2
(en)
|
2003-09-15 |
2008-07-15 |
Wyeth |
Protein tyrosine kinase enzyme inhibitors
|
EP1688439A4
(en)
|
2003-10-08 |
2007-12-19 |
Kyowa Hakko Kogyo Kk |
HYBRID PROTEIN COMPOSITION
|
JPWO2005035577A1
(ja)
|
2003-10-08 |
2007-11-22 |
協和醗酵工業株式会社 |
ガングリオシドgd3に特異的に結合する抗体組成物
|
US7612096B2
(en)
|
2003-10-23 |
2009-11-03 |
Celgene Corporation |
Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline
|
US7435596B2
(en)
|
2004-11-04 |
2008-10-14 |
St. Jude Children's Research Hospital, Inc. |
Modified cell line and method for expansion of NK cell
|
WO2005062916A2
(en)
|
2003-12-22 |
2005-07-14 |
Centocor, Inc. |
Methods for generating multimeric molecules
|
GB0329825D0
(en)
|
2003-12-23 |
2004-01-28 |
Celltech R&D Ltd |
Biological products
|
US20050266425A1
(en)
|
2003-12-31 |
2005-12-01 |
Vaccinex, Inc. |
Methods for producing and identifying multispecific antibodies
|
EP3476861A1
(en)
|
2004-01-07 |
2019-05-01 |
Novartis Vaccines and Diagnostics, Inc. |
M-csf-specific monoclonal antibody and uses thereof
|
CN1960728A
(zh)
|
2004-01-16 |
2007-05-09 |
密歇根大学董事会 |
构象受限的smac模拟物及其应用
|
US20100093645A1
(en)
|
2004-01-16 |
2010-04-15 |
Shaomeng Wang |
SMAC Peptidomimetics and the Uses Thereof
|
US8383575B2
(en)
|
2004-01-30 |
2013-02-26 |
Paul Scherrer Institut |
(DI)barnase-barstar complexes
|
US8263746B2
(en)
|
2004-02-06 |
2012-09-11 |
Morphosys Ag |
Anti-CD38 human antibodies and uses thereof
|
WO2006107617A2
(en)
|
2005-04-06 |
2006-10-12 |
Ibc Pharmaceuticals, Inc. |
Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
|
US7345081B2
(en)
|
2004-03-23 |
2008-03-18 |
Genentech, Inc. |
Azabicyclo-octane inhibitors of IAP
|
PL2253614T3
(pl)
|
2004-04-07 |
2013-03-29 |
Novartis Ag |
Inhibitory IAP
|
US20070161696A1
(en)
|
2004-04-23 |
2007-07-12 |
Zeldis Jerome B |
Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
|
MXPA06014065A
(es)
|
2004-06-01 |
2007-01-31 |
Genentech Inc |
Conjugados de droga-anticuerpo y metodos.
|
PT2298768E
(pt)
|
2004-06-11 |
2012-12-05 |
Japan Tobacco Inc |
Derivados de 5-amino-2,4,7-trioxo-3,4,7,8-tetra-hidro-2hpirido[ 2,3-d]pirimidina e compostos relacionados para o tratamento do cancro
|
EP1778718B1
(en)
|
2004-07-02 |
2014-10-08 |
Genentech, Inc. |
Inhibitors of iap
|
WO2006010118A2
(en)
|
2004-07-09 |
2006-01-26 |
The Regents Of The University Of Michigan |
Conformationally constrained smac mimetics and the uses thereof
|
EP1773348A4
(en)
|
2004-07-12 |
2009-05-20 |
Idun Pharmaceuticals Inc |
TETRA PEPTIDE ANALOGS
|
AU2005274937B2
(en)
|
2004-07-15 |
2011-08-18 |
Medivir Ab |
IAP binding compounds
|
JP2008512352A
(ja)
|
2004-07-17 |
2008-04-24 |
イムクローン システムズ インコーポレイティド |
新規な四価の二重特異性抗体
|
AU2005282700A1
(en)
|
2004-09-02 |
2006-03-16 |
Genentech, Inc. |
Heteromultimeric molecules
|
BRPI0514865A
(pt)
|
2004-09-03 |
2008-06-24 |
Celgene Corp |
processo para preparar um composto
|
WO2006039238A2
(en)
|
2004-09-30 |
2006-04-13 |
The Goverment Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Irta2 antibodies and methods of use
|
JP4731867B2
(ja)
|
2004-10-01 |
2011-07-27 |
国立大学法人三重大学 |
Cd8陽性の細胞傷害性tリンパ球の誘導方法
|
CA2583092C
(en)
|
2004-10-04 |
2014-12-30 |
Regents Of The University Of Minnesota |
Antiangiogenic calixarene-based peptide mimetics
|
AU2005311888A1
(en)
|
2004-12-01 |
2006-06-08 |
Celgene Corporation |
Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders
|
DE602005023646D1
(de)
|
2004-12-10 |
2010-10-28 |
Siemens Healthcare Diagnostics |
Für die vorhersage des ansprechens maligner neoplasie auf eine auf taxan beruhende medizinische behandlung geeignete genetische veränderung
|
ES2349110T5
(es)
|
2004-12-20 |
2013-11-27 |
Genentech, Inc. |
Inhibidores de IAP derivados de pirrolidina
|
MY146381A
(en)
|
2004-12-22 |
2012-08-15 |
Amgen Inc |
Compositions and methods relating relating to anti-igf-1 receptor antibodies
|
CA2594318A1
(en)
|
2005-01-12 |
2006-07-20 |
Medarex, Inc. |
Irta-2 antibodies and their uses
|
WO2006086469A2
(en)
|
2005-02-08 |
2006-08-17 |
Genzyme Corporation |
Antibodies to tgfbeta
|
JP4949373B2
(ja)
|
2005-03-10 |
2012-06-06 |
モルフォテック、インク. |
抗メソテリン抗体
|
PT2343320T
(pt)
|
2005-03-25 |
2018-01-23 |
Gitr Inc |
Anticorpos anti-gitr e as suas utilizações
|
AU2006232287B2
(en)
|
2005-03-31 |
2011-10-06 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for producing polypeptides by regulating polypeptide association
|
ES2707152T3
(es)
|
2005-04-15 |
2019-04-02 |
Macrogenics Inc |
Diacuerpos covalentes y usos de los mismos
|
AU2006244885B2
(en)
|
2005-05-09 |
2011-03-31 |
E. R. Squibb & Sons, L.L.C. |
Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
|
US20060263367A1
(en)
|
2005-05-23 |
2006-11-23 |
Fey Georg H |
Bispecific antibody devoid of Fc region and method of treatment using same
|
EP1726650A1
(en)
|
2005-05-27 |
2006-11-29 |
Universitätsklinikum Freiburg |
Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
|
JP2008546699A
(ja)
|
2005-06-15 |
2008-12-25 |
シェーリング コーポレイション |
抗igf1r抗体処方物
|
HUE026039T2
(en)
|
2005-07-01 |
2016-05-30 |
Squibb & Sons Llc |
Human monoclonal antibodies programmed for death ligand 1 (PD-L1)
|
WO2007004415A1
(ja)
|
2005-07-01 |
2007-01-11 |
Murata Manufacturing Co., Ltd. |
多層セラミック基板およびその製造方法ならびに多層セラミック基板作製用複合グリーンシート
|
TWI424147B
(zh)
|
2005-07-04 |
2014-01-21 |
尼康美景股份有限公司 |
Distance measuring device
|
ES2481402T3
(es)
|
2005-07-21 |
2014-07-30 |
Ardea Biosciences, Inc. |
Inhibidores de N-(arilamino)sulfonamida de MEK
|
WO2007024715A2
(en)
|
2005-08-19 |
2007-03-01 |
Abbott Laboratories |
Dual variable domain immunoglobin and uses thereof
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
EP1757622B1
(en)
|
2005-08-26 |
2009-12-23 |
PLS Design GmbH |
Bivalent IgY antibody constructs for diagnostic and therapeutic applications
|
MX2008002765A
(es)
*
|
2005-08-31 |
2008-04-07 |
Celgene Corp |
Compuestos de isoindol-imida y composiciones que la comprenden y metodos para usar los mismos.
|
WO2007044887A2
(en)
|
2005-10-11 |
2007-04-19 |
Transtarget, Inc. |
Method for producing a population of homogenous tetravalent bispecific antibodies
|
WO2007062466A1
(en)
|
2005-11-29 |
2007-06-07 |
The University Of Sydney |
Demibodies: dimerisation-activated therapeutic agents
|
WO2007067500A2
(en)
|
2005-12-05 |
2007-06-14 |
Genomic Health, Inc. |
Predictors of patient response to treatment with egfr inhibitors
|
CA2638902C
(en)
|
2005-12-08 |
2014-09-23 |
Medarex, Inc. |
Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1 antibodies
|
CA2633980A1
(en)
|
2005-12-29 |
2007-07-12 |
Anthrogenesis Corporation |
Improved composition for collecting and preserving placental stem cells and methods of using the composition
|
EP1806365A1
(en)
|
2006-01-05 |
2007-07-11 |
Boehringer Ingelheim International GmbH |
Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
|
AU2007207785B2
(en)
|
2006-01-13 |
2013-11-14 |
The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health |
Codon optimized IL- 15 and IL- 15R-alpha genes for expression in mammalian cells
|
JP2009526857A
(ja)
|
2006-02-15 |
2009-07-23 |
イムクローン・リミテッド・ライアビリティ・カンパニー |
機能性抗体
|
CA2646508A1
(en)
|
2006-03-17 |
2007-09-27 |
Biogen Idec Ma Inc. |
Stabilized polypeptide compositions
|
ES2363891T3
(es)
|
2006-03-20 |
2011-08-18 |
The Regents Of The University Of California |
Anticuerpos contra el antígeno de células troncales de la próstata (psca) modificados genéticamente para el direccionamiento al cáncer.
|
PL1999154T3
(pl)
|
2006-03-24 |
2013-03-29 |
Merck Patent Gmbh |
Skonstruowane metodami inżynierii heterodimeryczne domeny białkowe
|
WO2007112362A2
(en)
|
2006-03-24 |
2007-10-04 |
The Regents Of The University Of California |
Construction of a multivalent scfv through alkyne-azide 1,3-dipolar cycloaddition
|
JP5165672B2
(ja)
|
2006-03-29 |
2013-03-21 |
キングス カレッジ ロンドン |
Tshrに対するアゴニスト抗体
|
JP5144499B2
(ja)
|
2006-03-31 |
2013-02-13 |
中外製薬株式会社 |
二重特異性抗体を精製するための抗体改変方法
|
ES2654847T3
(es)
|
2006-04-19 |
2018-02-15 |
Novartis Ag |
Compuestos de benzoxazol y benzotiazol sustituidos en 6-O y métodos para inhibir la señalización CSF-1R
|
TWI395754B
(zh)
|
2006-04-24 |
2013-05-11 |
Amgen Inc |
人類化之c-kit抗體
|
AU2007248019B2
(en)
|
2006-05-03 |
2012-10-11 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Chimeric T cell receptors and related materials and methods of use
|
WO2008011216A2
(en)
|
2006-05-16 |
2008-01-24 |
Pro-Pharmaceuticals, Inc. |
Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
|
US20070269827A1
(en)
|
2006-05-18 |
2007-11-22 |
Oklahoma Medical Research Foundation |
Predicting and Diagnosing Patients With Autoimmune Disease
|
EP2799449A1
(en)
|
2006-05-25 |
2014-11-05 |
Bayer Intellectual Property GmbH |
Dimeric molecular complexes
|
US20070274985A1
(en)
|
2006-05-26 |
2007-11-29 |
Stefan Dubel |
Antibody
|
NZ573646A
(en)
|
2006-06-12 |
2012-04-27 |
Wyeth Llc |
Single-chain multivalent binding proteins with effector function
|
KR101342035B1
(ko)
|
2006-06-20 |
2013-12-16 |
한국과학기술연구원 |
신장독성 및 부작용 유발 약물 검색용 바이오마커 및 이를이용한 신장독성 및 부작용 유발 약물 검색 방법
|
US8759297B2
(en)
|
2006-08-18 |
2014-06-24 |
Armagen Technologies, Inc. |
Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns
|
WO2008024725A1
(en)
|
2006-08-21 |
2008-02-28 |
Genentech, Inc. |
Aza-benzofuranyl compounds and methods of use
|
WO2008027236A2
(en)
|
2006-08-30 |
2008-03-06 |
Genentech, Inc. |
Multispecific antibodies
|
US8877780B2
(en)
|
2006-08-30 |
2014-11-04 |
Celgene Corporation |
5-substituted isoindoline compounds
|
WO2008040362A2
(en)
|
2006-10-04 |
2008-04-10 |
Københavns Universitet |
Generation of a cancer-specific immune response toward muc1 and cancer specific muc1 antibodies
|
FR2906808B1
(fr)
|
2006-10-10 |
2012-10-05 |
Univ Nantes |
Utilisation d'anticorps monoclonaux specifiques de la forme o-acetylee du ganglioside gd2 dans le traitement de certains cancers
|
MX2009004664A
(es)
|
2006-11-02 |
2009-10-12 |
Daniel J Capon |
Inmunoglobulinas hibridas con partes moviles.
|
NO346024B1
(no)
|
2006-11-22 |
2022-01-03 |
Incyte Holdings Corp |
Imidazotriaziner og imidazopyrimidiner som kinaseinhibitorer
|
EP2094697A1
(en)
|
2006-11-23 |
2009-09-02 |
Novartis AG |
5-sulfanylmethyl-pyrazolo [1,5-a]pyrimidin-7-ol derivatives as cxcr2 antagonists
|
JP2010510268A
(ja)
|
2006-11-23 |
2010-04-02 |
ノバルティス アーゲー |
Cxcr2アンタゴニストとしての5−スルファニルメチル−[1,2,4]トリアゾロ[1,5−a]ピリミジン−7−オール
|
EP2086947A1
(en)
|
2006-11-23 |
2009-08-12 |
Novartis AG |
Pyrimidines and their use as cxcr2 receptor antagonists
|
WO2008101234A2
(en)
|
2007-02-16 |
2008-08-21 |
Sloan-Kettering Institute For Cancer Research |
Anti ganglioside gd3 antibodies and uses thereof
|
WO2008103645A2
(en)
|
2007-02-19 |
2008-08-28 |
Wisconsin Alumni Research Foundation |
Prostate cancer and melanoma antigens
|
EP2144935A2
(en)
|
2007-03-29 |
2010-01-20 |
Technion Research & Development Foundation Ltd. |
Antibodies, methods and kits for diagnosing and treating melanoma
|
US9212230B2
(en)
|
2007-03-29 |
2015-12-15 |
Genmab A/S |
Bispecific antibodies and methods for production thereof
|
US8163279B2
(en)
|
2007-04-13 |
2012-04-24 |
Stemline Therapeutics, Inc. |
IL3Rα antibody conjugates and uses thereof
|
CA2682605A1
(en)
|
2007-04-18 |
2008-10-30 |
Zymogenetics, Inc. |
Single chain fc, methods of making and methods of treatment
|
EP1987839A1
(en)
|
2007-04-30 |
2008-11-05 |
I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale |
Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
|
KR20100024923A
(ko)
|
2007-04-30 |
2010-03-08 |
제넨테크, 인크. |
Iap의 억제제
|
US9244059B2
(en)
|
2007-04-30 |
2016-01-26 |
Immutep Parc Club Orsay |
Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
|
CN104109200B
(zh)
|
2007-05-11 |
2018-03-20 |
阿尔托生物科学有限公司 |
融合分子与il‑15变异体
|
JP2010190572A
(ja)
|
2007-06-01 |
2010-09-02 |
Sapporo Medical Univ |
IL13Ra2に対する抗体およびこれを含む診断・治療薬
|
SI2170959T1
(sl)
|
2007-06-18 |
2014-04-30 |
Merck Sharp & Dohme B.V. |
Protitelesa proti receptorjem pd-1 za humano programirano smrt
|
WO2009017679A2
(en)
|
2007-07-31 |
2009-02-05 |
Merck & Co., Inc. |
Igf-1r specific antibodies useful in the detection and diagnosis of cellular proliferative disorders
|
EP2069401A4
(en)
|
2007-07-31 |
2011-02-23 |
Medimmune Llc |
MULTISPECIENT EPITOP BINDING PROTEINS AND THEIR USE
|
EP2178914A2
(en)
|
2007-08-15 |
2010-04-28 |
Bayer Schering Pharma Aktiengesellschaft |
Monospecific and multispecific antibodies and method of use
|
EP2205242B1
(en)
|
2007-09-12 |
2015-04-15 |
Genentech, Inc. |
Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
|
EP2195017B1
(en)
|
2007-10-01 |
2014-10-22 |
Bristol-Myers Squibb Company |
Human antibodies that bind mesothelin, and uses thereof
|
EP2044949A1
(en)
|
2007-10-05 |
2009-04-08 |
Immutep |
Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
|
JP2009092508A
(ja)
|
2007-10-09 |
2009-04-30 |
Norihiro Nishimoto |
リウマチ治療剤の効果の予測方法
|
WO2009055730A1
(en)
|
2007-10-25 |
2009-04-30 |
Genentech, Inc. |
Process for making thienopyrimidine compounds
|
DK2215121T3
(en)
|
2007-11-26 |
2016-05-02 |
Bayer Ip Gmbh |
ANTI-mesothelin ANTIBODIES AND USES THEREOF
|
JP2011504740A
(ja)
|
2007-11-27 |
2011-02-17 |
アブリンクス エン.ヴェー. |
ヘテロ二量体サイトカイン及び/又はこれらの受容体に指向性を有するアミノ酸配列、並びにこれを含むポリペプチド
|
CA2706419A1
(en)
|
2007-11-30 |
2009-06-04 |
Glaxo Group Limited |
Antigen-binding constructs binding il-13
|
EP2227558A1
(en)
|
2007-11-30 |
2010-09-15 |
GlaxoSmithKline Biologicals SA |
Method for classifying cancer patients as responder or non-responder to immunotherapy
|
CA2706571C
(en)
|
2007-12-19 |
2012-11-27 |
Genentech, Inc. |
5-anilinoimidazopyridines and methods of use
|
US8242247B2
(en)
|
2007-12-21 |
2012-08-14 |
Hoffmann-La Roche Inc. |
Bivalent, bispecific antibodies
|
US8227577B2
(en)
|
2007-12-21 |
2012-07-24 |
Hoffman-La Roche Inc. |
Bivalent, bispecific antibodies
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
KR100957051B1
(ko)
|
2007-12-28 |
2010-05-13 |
한국과학기술연구원 |
니트로푸란토인 처리에 따른, 폐독성 유발 약물 검색용마커유전자 및 이를 이용한 검색 방법
|
SI2235064T1
(sl)
|
2008-01-07 |
2016-04-29 |
Amgen Inc. |
Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
|
GB2456390A
(en)
|
2008-01-15 |
2009-07-22 |
Glaxo Group Ltd |
Bipolar disorder treatments
|
WO2009094592A2
(en)
|
2008-01-23 |
2009-07-30 |
Perlegen Sciences, Inc. |
Genetic basis of alzheimer's disease and diagnosis and treatment thereof
|
US8747847B2
(en)
|
2008-02-11 |
2014-06-10 |
Curetech Ltd. |
Monoclonal antibodies for tumor treatment
|
BRPI0908529A2
(pt)
|
2008-02-26 |
2015-09-29 |
Novartis Ag |
composto orgânicos
|
EP2262837A4
(en)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
PD-1 BINDING PROTEINS
|
WO2009117122A2
(en)
|
2008-03-19 |
2009-09-24 |
Existence Genetics Llc |
Genetic analysis
|
WO2009137095A2
(en)
|
2008-05-08 |
2009-11-12 |
The Johns Hopkins University |
Compositions and methods for modulating an immune response
|
AR071891A1
(es)
|
2008-05-30 |
2010-07-21 |
Imclone Llc |
Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
|
US8168784B2
(en)
|
2008-06-20 |
2012-05-01 |
Abbott Laboratories |
Processes to make apoptosis promoters
|
GB0906579D0
(en)
|
2009-04-16 |
2009-05-20 |
Vernalis R&D Ltd |
Pharmaceuticals, compositions and methods of making and using the same
|
UA103198C2
(en)
|
2008-08-04 |
2013-09-25 |
Новартис Аг |
Squaramide derivatives as cxcr2 antagonists
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
WO2010020675A1
(en)
|
2008-08-22 |
2010-02-25 |
Novartis Ag |
Pyrrolopyrimidine compounds as cdk inhibitors
|
PE20110435A1
(es)
|
2008-08-25 |
2011-07-20 |
Amplimmune Inc |
Composiciones antagonistas del pd-1
|
AU2009288289B2
(en)
|
2008-08-25 |
2012-11-08 |
Amplimmune, Inc. |
PD-1 antagonists and methods of use thereof
|
AU2009290544B2
(en)
|
2008-09-12 |
2015-07-16 |
Oxford University Innovation Limited |
PD-1 specific antibodies and uses thereof
|
CA2737758C
(en)
|
2008-09-19 |
2017-10-31 |
Soldano Ferrone |
Monoclonal antibodies for cspg4 for the diagnosis and treatment of basal breast carcinoma
|
KR102097887B1
(ko)
|
2008-09-26 |
2020-04-06 |
다나-파버 캔서 인스티튜트 인크. |
인간 항-pd-1, pd-l1, 및 pd-l2 항체 및 그의 용도
|
EP2177615A1
(en)
|
2008-10-10 |
2010-04-21 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases
|
PL2358697T3
(pl)
*
|
2008-10-29 |
2016-04-29 |
Celgene Corp |
Związki izoindolinowe do zastosowania w leczeniu raka
|
WO2010063802A1
(en)
|
2008-12-05 |
2010-06-10 |
Novartis Ag |
3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists
|
CN114835812A
(zh)
|
2008-12-09 |
2022-08-02 |
霍夫曼-拉罗奇有限公司 |
抗-pd-l1抗体及它们用于增强t细胞功能的用途
|
EP2210891A1
(en)
|
2009-01-26 |
2010-07-28 |
Domain Therapeutics |
New adenosine receptor ligands and uses thereof
|
EP3192811A1
(en)
|
2009-02-09 |
2017-07-19 |
Université d'Aix-Marseille |
Pd-1 antibodies and pd-l1 antibodies and uses thereof
|
PL2408775T3
(pl)
|
2009-03-20 |
2015-10-30 |
Alfasigma Spa |
Utlenione pochodne triazolilopurynowe użyteczne jako ligandy receptora adenozynowego a2a i ich zastosowanie jako leków
|
BRPI1012560A2
(pt)
|
2009-04-01 |
2016-07-26 |
Genentech Inc |
anticorpos anti-fcrh5 e imunoconjugados e métodos de uso
|
PE20120878A1
(es)
|
2009-04-01 |
2012-08-06 |
Genentech Inc |
ANTICUERPOS ANTI-FcRH5 E INMUNOCONJUGADOS
|
CN102459346B
(zh)
|
2009-04-27 |
2016-10-26 |
昂考梅德药品有限公司 |
制造异源多聚体分子的方法
|
KR101732201B1
(ko)
|
2009-04-27 |
2017-05-02 |
교와 핫꼬 기린 가부시키가이샤 |
혈액 종양 치료를 목적으로 하는 항IL-3Rα 항체
|
US9212177B2
(en)
|
2009-08-05 |
2015-12-15 |
Versitech Limited |
Antiviral compounds and methods of making and using thereof
|
BR112012002331A2
(pt)
|
2009-08-05 |
2019-09-24 |
Versitech Ltd |
composição antiviral, composição farmacêutica e uso de quantidade efetiva de composição farmacêutica
|
TWI445708B
(zh)
|
2009-09-02 |
2014-07-21 |
Irm Llc |
作為tlr活性調節劑之化合物及組合物
|
ES2788869T3
(es)
|
2009-09-03 |
2020-10-23 |
Merck Sharp & Dohme |
Anticuerpos anti-GITR
|
WO2011056505A1
(en)
|
2009-10-26 |
2011-05-12 |
Abbott Laboratories |
Detection of chromosomal abnormalities associated with prognosis of non small cell lung cancer
|
EP2504028A4
(en)
|
2009-11-24 |
2014-04-09 |
Amplimmune Inc |
SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
|
HUE037159T2
(hu)
|
2009-11-24 |
2018-08-28 |
Medimmune Ltd |
Targetált kötõdõ ágensek B7-H1 ellen
|
EP3511023A1
(en)
|
2009-12-02 |
2019-07-17 |
Imaginab, Inc. |
J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
|
US8440693B2
(en)
|
2009-12-22 |
2013-05-14 |
Novartis Ag |
Substituted isoquinolinones and quinazolinones
|
HUE028629T2
(en)
|
2009-12-23 |
2016-12-28 |
Synimmune Gmbh |
Anti-FLT3 antibodies and ways of their use
|
HUE028640T2
(en)
|
2010-02-05 |
2016-12-28 |
Heptares Therapeutics Ltd |
1,2,4-triazin-4-amine derivative
|
SI2536706T1
(sl)
|
2010-02-11 |
2017-10-30 |
Celgene Corporation |
Derivati arilmetoksi izoindolina in sestavki,ki jih vsebujejo ter metode uporabe le-teh
|
KR20230044026A
(ko)
|
2010-02-24 |
2023-03-31 |
이뮤노젠 아이엔씨 |
엽산염 수용체 1 항체와 면역접합체 및 이들의 용도
|
WO2011110604A1
(en)
|
2010-03-11 |
2011-09-15 |
Ucb Pharma, S.A. |
Pd-1 antibody
|
ES2365960B1
(es)
|
2010-03-31 |
2012-06-04 |
Palobiofarma, S.L |
Nuevos antagonistas de los receptores de adenosina.
|
EA201201435A1
(ru)
|
2010-04-20 |
2013-04-30 |
Генмаб А/С |
ГЕТЕРОДИМЕРНЫЕ АНТИТЕЛО-Fc-СОДЕРЖАЩИЕ БЕЛКИ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
|
DK2569446T3
(en)
|
2010-05-12 |
2018-10-29 |
Steven E Schutzer |
DIAGNOSTIC MARKERS FOR NEUROPsychiatric Disease
|
US20120149715A1
(en)
|
2010-05-28 |
2012-06-14 |
Yi Tsun Richard Kao |
Compounds and methods for the treatment of viral infections
|
WO2011151941A1
(ja)
|
2010-06-04 |
2011-12-08 |
国立大学法人東京大学 |
制御性t細胞の増殖または集積を誘導する作用を有する組成物
|
JP2013528223A
(ja)
|
2010-06-10 |
2013-07-08 |
アラゴン ファーマシューティカルズ,インク. |
エストロゲン受容体モジュレーターおよびその用途
|
AU2011262758B8
(en)
|
2010-06-11 |
2014-09-04 |
Kyowa Kirin Co., Ltd. |
Anti-tim-3 antibody
|
WO2011159847A2
(en)
|
2010-06-15 |
2011-12-22 |
The Regents Of The University Of California |
Receptor tyrosine kinase-like orphan receptor 1 (ror1) single chain fv antibody fragment conjugates and methods of use thereof
|
US8853423B2
(en)
|
2010-06-17 |
2014-10-07 |
Seragon Pharmaceuticals, Inc. |
Indane estrogen receptor modulators and uses thereof
|
CA2802344C
(en)
|
2010-06-18 |
2023-06-13 |
The Brigham And Women's Hospital, Inc. |
Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
|
EP2582722A4
(en)
|
2010-06-19 |
2013-12-18 |
Sloan Kettering Inst Cancer |
ANTIBODIES AGAINST GD2
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
US20130281304A1
(en)
|
2010-08-13 |
2013-10-24 |
Andrew P. Feinberg |
Comprehensive Methylome Map of Myeloid and Lymphoid Commitment from Hematopoietic Proenitors
|
WO2012033885A1
(en)
|
2010-09-08 |
2012-03-15 |
Baylor College Of Medicine |
Immunotherapy of cancer using genetically engineered gd2-specific t cells
|
GB2483736B
(en)
|
2010-09-16 |
2012-08-29 |
Aragon Pharmaceuticals Inc |
Estrogen receptor modulators and uses thereof
|
EP2630158B1
(en)
|
2010-10-22 |
2018-12-12 |
Dana-Farber Cancer Institute, Inc. |
Discovery of regulatory t cells programmed to suppress an immune response
|
TWI619811B
(zh)
|
2010-11-08 |
2018-04-01 |
諾華公司 |
趨化細胞素受體結合多肽
|
PT3214091T
(pt)
|
2010-12-09 |
2019-01-11 |
Univ Pennsylvania |
Utilização de células t modificadas por recetor de antigénio quimérico para tratar o cancro
|
JOP20210044A1
(ar)
|
2010-12-30 |
2017-06-16 |
Takeda Pharmaceuticals Co |
الأجسام المضادة لـ cd38
|
EP3323833B1
(en)
|
2011-04-01 |
2019-12-04 |
Memorial Sloan-Kettering Cancer Center |
T cell receptor-like bispecific antibodies specific for a wt1 peptide presented by hla-a2
|
RU2625034C2
(ru)
|
2011-04-20 |
2017-07-11 |
МЕДИММЬЮН, ЭлЭлСи |
Антитела и другие молекулы, которые связывают в7-н1 и pd-1
|
AR086044A1
(es)
|
2011-05-12 |
2013-11-13 |
Imclone Llc |
Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos
|
EP4338754A2
(en)
|
2011-05-27 |
2024-03-20 |
Glaxo Group Limited |
Antigen binding proteins
|
SI2714735T1
(sl)
|
2011-06-03 |
2021-12-31 |
Xoma Technology Ltd. |
Protitelesa, specifična za TGF-beta
|
EP2717876B1
(en)
|
2011-06-06 |
2018-12-19 |
University of Iowa Research Foundation |
Substances and compostions for use in methods of inhibiting muscle atrophy
|
US20140234342A1
(en)
|
2011-06-21 |
2014-08-21 |
Innate Pharma |
Nkp46-mediated nk cell tuning
|
EP2537933A1
(en)
|
2011-06-24 |
2012-12-26 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
An IL-15 and IL-15Ralpha sushi domain based immunocytokines
|
US9910039B2
(en)
|
2011-07-01 |
2018-03-06 |
Beckman Coulter, Inc. |
Regulatory T cells and methods of identifying, obtaining and using to treat immuno-based disorders
|
WO2013006490A2
(en)
|
2011-07-01 |
2013-01-10 |
Cellerant Therapeutics, Inc. |
Antibodies that specifically bind to tim3
|
MY193562A
(en)
|
2011-08-01 |
2022-10-19 |
Genentech Inc |
Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
|
EA201490552A1
(ru)
|
2011-09-02 |
2014-11-28 |
Новартис Аг |
Холиновая соль замещенного циклобутендиона, обладающая противовоспалительной способностью
|
WO2013037118A1
(zh)
|
2011-09-16 |
2013-03-21 |
上海长海医院 |
***癌的生物学标志物、治疗靶点及其用途
|
EP2756521A4
(en)
|
2011-09-16 |
2015-04-22 |
Univ Pennsylvania |
RNA-MANIPULATED T-CELLS FOR THE TREATMENT OF CANCER
|
US20140255363A1
(en)
|
2011-09-16 |
2014-09-11 |
Baylor College Of Medicine |
Targeting the tumor microenvironment using manipulated nkt cells
|
ITMO20110270A1
(it)
|
2011-10-25 |
2013-04-26 |
Sara Caldrer |
Una cellula effettrice modificata per il trattamento di neoplasie esprimenti il disialonganglioside gd2
|
LT2771364T
(lt)
|
2011-10-27 |
2019-09-10 |
Genmab A/S |
Heterodimerinių baltymų gamyba
|
US9272002B2
(en)
|
2011-10-28 |
2016-03-01 |
The Trustees Of The University Of Pennsylvania |
Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
|
US10391126B2
(en)
|
2011-11-18 |
2019-08-27 |
Board Of Regents, The University Of Texas System |
CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA
|
AU2012344260B2
(en)
|
2011-11-28 |
2017-09-07 |
Merck Patent Gmbh |
Anti-PD-L1 antibodies and uses thereof
|
CA2892588A1
(en)
|
2011-12-01 |
2013-06-06 |
School Corporation, Azabu Veterinary Medicine Educational Institution |
Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
|
US9439768B2
(en)
|
2011-12-08 |
2016-09-13 |
Imds Llc |
Glenoid vault fixation
|
US9481866B2
(en)
|
2011-12-16 |
2016-11-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of producing T cell populations enriched for stable regulatory T-cells
|
WO2013098797A2
(en)
|
2011-12-31 |
2013-07-04 |
Kuriakose Moni Abraham |
Diagnostic tests for predicting prognosis, recurrence, resistance or sensitivity to therapy and metastatic status in cancer
|
US8815926B2
(en)
|
2012-01-26 |
2014-08-26 |
Novartis Ag |
Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
|
EP3594245A1
(en)
|
2012-02-13 |
2020-01-15 |
Seattle Children's Hospital d/b/a Seattle Children's Research Institute |
Bispecific chimeric antigen receptors and therapeutic uses thereof
|
SG11201404285VA
(en)
|
2012-02-22 |
2014-10-30 |
Univ Pennsylvania |
Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
|
AU2013225721B2
(en)
|
2012-03-02 |
2018-06-14 |
The Regents Of The University Of California |
Expansion of alloantigen-reactive regulatory T cells
|
AU2013235726B2
(en)
|
2012-03-23 |
2017-04-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-mesothelin chimeric antigen receptors
|
GB201207297D0
(en)
|
2012-04-26 |
2012-06-06 |
Senzagen Ab |
Analytical methods and arrays for use in the same
|
AR090903A1
(es)
|
2012-05-01 |
2014-12-17 |
Genentech Inc |
Anticuerpos e inmunoconjugados anti-pmel17
|
US9328174B2
(en)
|
2012-05-09 |
2016-05-03 |
Novartis Ag |
Chemokine receptor binding polypeptides
|
ES2924722T3
(es)
|
2012-05-18 |
2022-10-10 |
Aptevo Res & Development Llc |
Unión de inmunofusión de scFv biespecífico (BIf) a CD123 y CD3
|
WO2013179174A1
(en)
|
2012-05-29 |
2013-12-05 |
Koninklijke Philips N.V. |
Lighting arrangement
|
CN115093480A
(zh)
|
2012-05-31 |
2022-09-23 |
索伦托药业有限公司 |
与pd-l1结合的抗原结合蛋白
|
GB201213571D0
(en)
|
2012-07-31 |
2012-09-12 |
Univ Leuven Kath |
Growth factor cocktail to enhnce osteogenic differentiayion of mesenchymal
|
WO2013192294A1
(en)
|
2012-06-20 |
2013-12-27 |
Boston 3T Biotechnologies, Inc. |
Cellular therapies for treating and preventing cancers and other immune system disorders
|
AR091649A1
(es)
|
2012-07-02 |
2015-02-18 |
Bristol Myers Squibb Co |
Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
|
EP2682750A1
(en)
|
2012-07-02 |
2014-01-08 |
Sotio a.s. |
In vitro method for the diagnosis and surveillance of cancer
|
CN111499755A
(zh)
|
2012-08-03 |
2020-08-07 |
丹娜法伯癌症研究院 |
抗-pd-l1和pd-l2双结合抗体单一试剂及其使用方法
|
BR112015002816A8
(pt)
|
2012-08-20 |
2023-04-18 |
Hutchinson Fred Cancer Res |
Método e composições para imunoterapia celular
|
JP6306592B2
(ja)
|
2012-09-10 |
2018-04-04 |
セルジーン コーポレイション |
局所進行乳癌を治療するための方法
|
ES2773921T3
(es)
|
2012-09-17 |
2020-07-15 |
Galectin Therapeutics Inc |
Método para mejorar las inmunoterapias específicas en el tratamiento del cáncer
|
CN107892719B
(zh)
|
2012-10-04 |
2022-01-14 |
达纳-法伯癌症研究所公司 |
人单克隆抗-pd-l1抗体和使用方法
|
CA2886120A1
(en)
|
2012-10-08 |
2014-04-17 |
St. Jude Children's Research Hospital |
Therapies based on control of regulatory t cell stability and function via a neuropilin-1:semaphorin axis
|
EP2911684B1
(en)
|
2012-10-24 |
2019-06-19 |
Novartis Ag |
Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes
|
TW201425336A
(zh)
|
2012-12-07 |
2014-07-01 |
Amgen Inc |
Bcma抗原結合蛋白質
|
AR093984A1
(es)
|
2012-12-21 |
2015-07-01 |
Merck Sharp & Dohme |
Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
|
ES2829499T3
(es)
|
2013-02-05 |
2021-06-01 |
Engmab Sarl |
Método para la selección de anticuerpos contra BCMA
|
US20160007893A1
(en)
|
2013-02-06 |
2016-01-14 |
Loxbridge Research Llp |
Systems and methods for early disease detection and real-time disease monitoring
|
EP2958907B1
(en)
|
2013-02-19 |
2018-02-28 |
Novartis AG |
Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
|
ES2760023T3
(es)
|
2013-02-20 |
2020-05-12 |
Univ Pennsylvania |
Tratamiento del cáncer utilizando receptor de antígeno quimérico anti-EGFRvIII humanizado
|
TW201446794A
(zh)
|
2013-02-20 |
2014-12-16 |
Novartis Ag |
利用抗-cd123嵌合抗原受體工程化t細胞之初級人類白血病有效靶向
|
WO2014153069A2
(en)
|
2013-03-14 |
2014-09-25 |
Children's Medical Center Corporation |
Compositions and methods for reprogramming hematopoietic stem cell lineages
|
WO2014138819A1
(en)
|
2013-03-14 |
2014-09-18 |
Csl Limited |
Agents that neutralize il-3 signaling and uses thereof
|
US20160031996A1
(en)
|
2013-03-14 |
2016-02-04 |
Csl Limited |
Anti il-3r alpha agents and uses thereof
|
SG11201506723XA
(en)
|
2013-03-15 |
2015-09-29 |
Veracyte Inc |
Methods and compositions for classification of samples
|
ME03796B
(me)
|
2013-03-15 |
2021-04-20 |
Glaxosmithkline Ip Dev Ltd |
Anti-lag-3 vezujući proteini
|
US9657105B2
(en)
|
2013-03-15 |
2017-05-23 |
City Of Hope |
CD123-specific chimeric antigen receptor redirected T cells and methods of their use
|
AR095374A1
(es)
|
2013-03-15 |
2015-10-14 |
Amgen Res (Munich) Gmbh |
Moléculas de unión para bcma y cd3
|
TWI654206B
(zh)
|
2013-03-16 |
2019-03-21 |
諾華公司 |
使用人類化抗-cd19嵌合抗原受體治療癌症
|
DK2981607T3
(da)
|
2013-04-03 |
2020-11-16 |
Memorial Sloan Kettering Cancer Center |
Effektiv generering af tumormålrettede t-celler afledt af pluripotente stamceller
|
US9815897B2
(en)
|
2013-05-02 |
2017-11-14 |
Anaptysbio, Inc. |
Antibodies directed against programmed death-1 (PD-1)
|
CN105683217B
(zh)
|
2013-05-31 |
2019-12-10 |
索伦托治疗有限公司 |
与pd-1结合的抗原结合蛋白
|
WO2014200952A2
(en)
|
2013-06-10 |
2014-12-18 |
Suregene, Llc |
Genetic markers of antipsychotic response
|
WO2014209804A1
(en)
|
2013-06-24 |
2014-12-31 |
Biomed Valley Discoveries, Inc. |
Bispecific antibodies
|
AR096687A1
(es)
|
2013-06-24 |
2016-01-27 |
Genentech Inc |
Anticuerpos anti-fcrh5
|
AR097306A1
(es)
|
2013-08-20 |
2016-03-02 |
Merck Sharp & Dohme |
Modulación de la inmunidad tumoral
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
WO2015035367A1
(en)
|
2013-09-09 |
2015-03-12 |
The Scripps Research Institute |
Methods and systems for analysis of organ transplantation
|
CN112552401B
(zh)
|
2013-09-13 |
2023-08-25 |
广州百济神州生物制药有限公司 |
抗pd1抗体及其作为治疗剂与诊断剂的用途
|
WO2015050875A1
(en)
|
2013-10-01 |
2015-04-09 |
The Regents Of The University Of California |
Endometriosis classifier
|
UY35790A
(es)
|
2013-10-21 |
2015-05-29 |
Teva Pharma |
Marcadores genéticos que predicen la respuesta al acetato de glatiramer
|
US10202454B2
(en)
|
2013-10-25 |
2019-02-12 |
Dana-Farber Cancer Institute, Inc. |
Anti-PD-L1 monoclonal antibodies and fragments thereof
|
WO2015081158A1
(en)
|
2013-11-26 |
2015-06-04 |
Bristol-Myers Squibb Company |
Method of treating hiv by disrupting pd-1/pd-l1 signaling
|
DK3081576T3
(da)
|
2013-12-12 |
2019-10-21 |
Shanghai hengrui pharmaceutical co ltd |
Pd-1-antistof, antigenbindende fragment deraf og medicinsk anvendelse deraf
|
EP3083964B1
(en)
|
2013-12-19 |
2022-01-26 |
Novartis AG |
Human mesothelin chimeric antigen receptors and uses thereof
|
DK3094351T3
(da)
|
2014-01-15 |
2022-02-21 |
Kadmon Corp Llc |
Immunmodulatoriske midler
|
WO2015109212A1
(en)
|
2014-01-17 |
2015-07-23 |
Pfizer Inc. |
Anti-il-2 antibodies and compositions and uses thereof
|
WO2015107196A1
(en)
|
2014-01-20 |
2015-07-23 |
Institut Curie |
Use of thalidomide or analogs thereof for preventing neurologic disorders induced by brain irradiation
|
WO2015112534A2
(en)
|
2014-01-21 |
2015-07-30 |
Medimmune, Llc |
Compositions and methods for modulating and redirecting immune responses
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗pd-l1之人類抗體
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對pd-1的人類抗體
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
PL3556775T3
(pl)
|
2014-01-28 |
2022-01-31 |
Bristol-Myers Squibb Company |
Przeciwciała anty-lag-3 w leczeniu nowotworów hematologicznych
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
CN106488767A
(zh)
|
2014-03-13 |
2017-03-08 |
豪夫迈·罗氏有限公司 |
调节***受体突变体的方法和组合物
|
KR102442436B1
(ko)
|
2014-03-14 |
2022-09-15 |
노파르티스 아게 |
Lag-3에 대한 항체 분자 및 그의 용도
|
ES2939760T3
(es)
|
2014-03-15 |
2023-04-26 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico para antígenos
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
JP6778114B2
(ja)
|
2014-04-14 |
2020-10-28 |
アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. |
イミド系タンパク質分解モジュレーター及び関連する使用方法
|
US20160058872A1
(en)
|
2014-04-14 |
2016-03-03 |
Arvinas, Inc. |
Imide-based modulators of proteolysis and associated methods of use
|
MA47849A
(fr)
|
2014-05-28 |
2020-01-29 |
Agenus Inc |
Anticorps anti-gitr et leurs procédés d'utilisation
|
EP3149042B1
(en)
|
2014-05-29 |
2019-08-28 |
Spring Bioscience Corporation |
Pd-l1 antibodies and uses thereof
|
WO2015187835A2
(en)
|
2014-06-06 |
2015-12-10 |
Bristol-Myers Squibb Company |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
|
WO2015195163A1
(en)
|
2014-06-20 |
2015-12-23 |
R-Pharm Overseas, Inc. |
Pd-l1 antagonist fully human antibody
|
TWI693232B
(zh)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
|
CN110156892B
(zh)
|
2014-07-03 |
2023-05-16 |
百济神州有限公司 |
抗pd-l1抗体及其作为治疗剂及诊断剂的用途
|
CA2955386A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Treatment of cancer using humanized anti-bcma chimeric antigen receptor
|
TWI719942B
(zh)
|
2014-07-21 |
2021-03-01 |
瑞士商諾華公司 |
使用cd33嵌合抗原受體治療癌症
|
EP3171882A1
(en)
|
2014-07-21 |
2017-05-31 |
Novartis AG |
Treatment of cancer using a cll-1 chimeric antigen receptor
|
US20170226216A1
(en)
|
2014-07-24 |
2017-08-10 |
Bluebird Bio, Inc. |
Bcma chimeric antigen receptors
|
CN112410363A
(zh)
|
2014-08-19 |
2021-02-26 |
诺华股份有限公司 |
抗cd123嵌合抗原受体(car)用于癌症治疗
|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
WO2016054638A1
(en)
|
2014-10-03 |
2016-04-07 |
Dana-Farber Cancer Institute, Inc. |
Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
AU2015333687B2
(en)
|
2014-10-14 |
2021-03-18 |
Dana-Farber Cancer Institute, Inc. |
Antibody molecules to PD-L1 and uses thereof
|
US10017492B2
(en)
*
|
2014-10-30 |
2018-07-10 |
Kangpu Biopharmaceuticals, Ltd. |
Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof
|
KR102011205B1
(ko)
|
2014-11-06 |
2019-08-14 |
에프. 호프만-라 로슈 아게 |
항-tim3 항체 및 사용 방법
|
EP3789403A1
(en)
|
2014-11-11 |
2021-03-10 |
MedImmune Limited |
Therapeutic combinations comprising anti-cd73 antibodies and a2a receptor inhibitor and uses thereof
|
EP4112738A1
(en)
|
2014-12-05 |
2023-01-04 |
Foundation Medicine, Inc. |
Multigene analysis of tumor samples
|
TWI595006B
(zh)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
抗pd-1抗體類和使用彼等之方法
|
EP3034620A1
(en)
|
2014-12-17 |
2016-06-22 |
Diaxonhit |
Compositions and methods for diagnosing thyroid cancer
|
WO2016103269A1
(en)
|
2014-12-23 |
2016-06-30 |
Ramot At Tel-Aviv University Ltd. |
Populations of neural progenitor cells and methods of producing and using same
|
US20160200815A1
(en)
|
2015-01-05 |
2016-07-14 |
Jounce Therapeutics, Inc. |
Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
|
NZ734082A
(en)
|
2015-01-20 |
2019-01-25 |
Boehringer Ingelheim Animal Health Usa Inc |
Anthelmintic compounds, compositions and method of using thereof
|
EP3050570A1
(en)
|
2015-01-31 |
2016-08-03 |
Neurovision Pharma GmbH |
Pharmaceutical composition consisting of a combination of G-CSF with GM-CSF
|
WO2016140974A1
(en)
|
2015-03-01 |
2016-09-09 |
Novena Therapeutics Inc. |
Process for measuring tumor response to an initial oncology treatment
|
WO2016144803A2
(en)
|
2015-03-06 |
2016-09-15 |
Sorrento Therapeutics, Inc. |
Antibody therapeutics that bind tim3
|
MA41867A
(fr)
|
2015-04-01 |
2018-02-06 |
Anaptysbio Inc |
Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3)
|
EP3298004B1
(en)
|
2015-05-22 |
2021-01-06 |
Biotheryx Inc. |
Compounds targeting proteins, compositions, methods, and uses thereof
|
EP3304076A4
(en)
|
2015-06-02 |
2018-12-19 |
Celgene Corporation |
Methods for determining drug efficacy for treatment of cancer using ratios of cereblon associated proteins
|
BR112017025297A2
(pt)
|
2015-06-03 |
2018-08-14 |
Bristol-Myers Squibb Company |
anticorpos anti-gitr para diagnóstico do câncer
|
US20190192565A1
(en)
|
2015-06-03 |
2019-06-27 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce conversion of regulatory t cells into effector t cells for cancer immunotherapy
|
ES2862469T3
(es)
|
2015-06-04 |
2021-10-07 |
Arvinas Operations Inc |
Moduladores de proteólisis a base de imidas y métodos de uso asociados
|
CN108135945A
(zh)
|
2015-06-22 |
2018-06-08 |
哈佛大学校长及研究员协会 |
固有层调节性t细胞的诱导
|
CA2992298A1
(en)
|
2015-07-23 |
2017-01-26 |
Inhibrx Lp |
Multivalent and multispecific gitr-binding fusion proteins
|
KR102114562B1
(ko)
|
2015-08-11 |
2020-05-26 |
노파르티스 아게 |
암의 치료에 사용하기 위한 5-브로모-2,6-디-(1h-피라졸-1-일)피리미딘-4-아민
|
JP2018522571A
(ja)
|
2015-08-12 |
2018-08-16 |
メディミューン リミテッド |
Gitrl融合タンパク質およびその使用
|
BR112018002757A8
(pt)
|
2015-08-13 |
2023-04-11 |
Merck Sharp & Dohme |
Composto, composição farmacêutica, e, métodos para induzir uma resposta imune, para induzir uma produção de interferon tipo i e para tratamento de um distúrbio
|
WO2017042337A1
(en)
|
2015-09-09 |
2017-03-16 |
Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmhotz-Gemeinschaft |
Short-chain fatty acids for use in the treatment of cardiovascular disease
|
WO2017044979A2
(en)
|
2015-09-11 |
2017-03-16 |
Ventria Bioscience Inc. |
Lactoferrin compositions and methods for modulation of t cell subtypes and treatment of autoimmune diseases
|
WO2017058881A1
(en)
|
2015-09-28 |
2017-04-06 |
The Trustees Of Columbia University In The City Of New York |
Use of pentoxifylline with immune checkpoint-blockade therapies for the treatment of melanoma
|
AU2016330967B2
(en)
|
2015-09-30 |
2021-03-25 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Thalidomide analogs and methods of use
|
WO2017075451A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
|
WO2017075465A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
|
WO2017075478A2
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
|
EP3384013A4
(en)
|
2015-12-04 |
2019-07-10 |
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. |
T-CELLS SPECIFIC TO ANTIGEN TO INDUCE IMMUNE TOLERANCE
|
EP3429603B1
(en)
|
2016-03-15 |
2021-12-29 |
Children's Medical Center Corporation |
Methods and compositions relating to hematopoietic stem cell expansion
|
WO2017176958A1
(en)
|
2016-04-06 |
2017-10-12 |
The Regents Of The University Of Michigan |
Monofunctional intermediates for ligand-dependent target protein degradation
|
EP3452101A2
(en)
|
2016-05-04 |
2019-03-13 |
CureVac AG |
Rna encoding a therapeutic protein
|
WO2017197056A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
Bromodomain targeting degronimers for target protein degradation
|
CN109790143A
(zh)
|
2016-05-10 |
2019-05-21 |
C4医药公司 |
用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
|
PL3660004T3
(pl)
|
2016-10-11 |
2023-10-02 |
Arvinas Operations, Inc. |
Związki i sposoby do ukierunkowanej degradacji receptora androgenowego
|
JP7286539B2
(ja)
|
2016-11-01 |
2023-06-05 |
アルビナス・オペレーションズ・インコーポレイテッド |
タウタンパク質標的化protac、および関連使用方法
|
RU2750484C2
(ru)
|
2016-12-01 |
2021-06-28 |
Эрвинэс Оперейшнс, Инк. |
Производные тетрагидронафталина и тетрагидроизохинолина в качестве разрушителей эстрогенового рецептора
|
CN110741004B
(zh)
|
2016-12-23 |
2023-10-17 |
阿尔维纳斯运营股份有限公司 |
用于迅速加速性纤维肉瘤多肽的靶向降解的化合物和方法
|
EP3559006A4
(en)
|
2016-12-23 |
2021-03-03 |
Arvinas Operations, Inc. |
COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF FETAL LIVER KINASE POLYPEPTIDES
|
CN110753693A
(zh)
|
2016-12-23 |
2020-02-04 |
阿尔维纳斯运营股份有限公司 |
Egfr蛋白水解靶向嵌合分子和相关使用方法
|
US11191741B2
(en)
|
2016-12-24 |
2021-12-07 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
|
MX2019008934A
(es)
|
2017-01-26 |
2019-11-05 |
Arvinas Operations Inc |
Moduladores de la proteolisis del receptor de estrogeno y métodos asociados de uso,.
|
US20180215731A1
(en)
|
2017-01-31 |
2018-08-02 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
CN106932576A
(zh)
|
2017-03-22 |
2017-07-07 |
山东大学深圳研究院 |
一种人调节性t细胞的免疫抑制功能的检测方法
|
TWI793151B
(zh)
*
|
2017-08-23 |
2023-02-21 |
瑞士商諾華公司 |
3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
|
CN111629749A
(zh)
*
|
2017-10-18 |
2020-09-04 |
诺华股份有限公司 |
用于选择性蛋白质降解的组合物和方法
|
EP3773576A4
(en)
|
2018-03-26 |
2021-12-29 |
C4 Therapeutics, Inc. |
Cereblon binders for the degradation of ikaros
|
BR122022012697B1
(pt)
|
2018-07-10 |
2023-04-04 |
Novartis Ag |
Usos de derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6- diona, e kit
|